Page last updated: 2024-08-25

nsc 251635 and bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii)

nsc 251635 has been researched along with bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Perez-Soler, R; Sugarman, SM	1

Reviews

1 review(s) available for nsc 251635 and bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii)

Article	Year
Liposomes in the treatment of malignancy: a clinical perspective. Critical reviews in oncology/hematology, 1992, Volume: 12, Issue:3 Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Antigens, Neoplasm; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Carriers; Drug Evaluation; Drug Screening Assays, Antitumor; Humans; Immunotherapy; Liposomes; Macrophage Activation; Macrophages; Melanoma-Specific Antigens; Neoplasm Proteins; Neoplasms; Organoplatinum Compounds; Phosphatidylethanolamines; Quinazolines; Treatment Outcome	1992

Article

Year

Liposomes in the treatment of malignancy: a clinical perspective.

Critical reviews in oncology/hematology, 1992, Volume: 12, Issue:3

Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Antigens, Neoplasm; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Carriers; Drug Evaluation; Drug Screening Assays, Antitumor; Humans; Immunotherapy; Liposomes; Macrophage Activation; Macrophages; Melanoma-Specific Antigens; Neoplasm Proteins; Neoplasms; Organoplatinum Compounds; Phosphatidylethanolamines; Quinazolines; Treatment Outcome

1992